Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Brain Drug Firm Envoy Is Going To Takeda

by Michael McCoy
November 12, 2012 | A version of this story appeared in Volume 90, Issue 46

Takeda Pharmaceutical has agreed to acquire Envoy Therapeutics for as much as $140 million, a sum that includes an up-front sum and progress-dependent preclinical milestone payments. Based in Jupiter, Fla., Envoy uses its bacTRAP technology to label and extract the protein-making components of cells. Takeda says the technology is especially powerful in tissues of the brain. Takeda first invested in Envoy in 2009. It plans to move most of the firm’s 21 employees to its San Diego R&D facility early next year.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.